Brief: Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001
06/03/2025 14:37
March 6 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP001 EXPECTS THAT PRODUCT WILL BE APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA FOR MARKETING IN NEAR FUTURE Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit